Tofacitinib

Hill Holliday launches new healthcare practice, Hill Holiday Quest, led by former Pfizer executive Christy Lopé. The practice aims to tackle healthcare challenges from a client perspective, leveraging Hill Holliday’s DTC experience and Lopé’s expertise in consumer health and wellness brands. Quest seeks to bring fresh energy to the healthcare market by drawing on Hill Holliday’s broader network of non-health verticals.

A systematic review of real-world studies on advanced therapies for moderate-to-severe ulcerative colitis found Entyvio and Xeljanz most commonly studied, with Xeljanz showing higher remission rates. Entyvio outperformed TNF inhibitors in remission rates, while Remicade was most effective among TNF inhibitors. Safety profiles were similar across all therapies, though study limitations warrant further research.

ICER found five drugs—Biktarvy, Darzalex, Entresto, Cabometyx, and Xeljanz—had price hikes not backed by new clinical evidence, adding $815M to U.S. payer costs in 2023.